Novartis India Reports Strong Profit Growth Amid Declining Net Sales in June 2025 Results

Jul 29 2025 06:33 PM IST
share
Share Via
Novartis India has reported its financial results for the quarter ending June 2025, highlighting a 40.82% year-on-year growth in Profit After Tax at Rs 56.92 crore. The company also achieved its highest Operating Profit in five quarters, though Net Sales declined by 5.14% year-on-year.
Novartis India, a player in the Pharmaceuticals & Biotechnology sector, has released its financial results for the quarter ending June 2025. The evaluation changes reflect a notable shift, with the stock's score adjusting to 7 from 10 over the past three months.

The financial data reveals several positive aspects for Novartis India. The Profit After Tax (PAT) for the latest six months stands at Rs 56.92 crore, showcasing a year-on-year growth of 40.82%. Additionally, the company achieved its highest Operating Profit (PBDIT) in the last five quarters, reaching Rs 27.24 crore, indicating a favorable near-term trend. The Operating Profit Margin also peaked at 31.11%, suggesting an enhancement in the company's operational efficiency. Furthermore, the Profit Before Tax less Other Income (PBT) recorded its highest figure in the last five quarters at Rs 26.61 crore, reinforcing the positive near-term outlook.

Conversely, the financial results indicate challenges as well. Net Sales for the quarter amounted to Rs 87.55 crore, reflecting a year-on-year decline of 5.14%, which points to a negative near-term sales trend.

For further insights, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Why is Novartis India falling/rising?
Dec 05 2025 12:56 AM IST
share
Share Via
Why is Novartis India falling/rising?
Nov 06 2025 10:05 PM IST
share
Share Via
Is Novartis India overvalued or undervalued?
Nov 05 2025 08:06 AM IST
share
Share Via
Is Novartis India overvalued or undervalued?
Nov 03 2025 08:04 AM IST
share
Share Via
Is Novartis India overvalued or undervalued?
Nov 02 2025 08:04 AM IST
share
Share Via
Is Novartis India overvalued or undervalued?
Nov 01 2025 08:05 AM IST
share
Share Via